Oral Treatment Infigratinib for Achondroplasia Shows Significant Growth Results

BridgeBio Pharma has announced successful results from its pivotal Phase 3 PROPEL 3 clinical trial for infigratinib, an experimental treatment for achondroplasia, the most common form of dwarfism. The late-stage data showed that children receiving the drug grew significantly taller than those in the control group, potentially setting a new standard for care in a market currently dominated by injectable therapies.

The trial, which included approximately 110 children, met its primary endpoint by demonstrating an annualized height velocity (AHV) between 1.74 and 2.1 centimeters greater than the placebo group over 52 weeks. Beyond the primary goal, infigratinib set records for randomized achondroplasia studies in several other growth metrics. Notably, the drug was well tolerated, with no serious adverse events or trial discontinuations related to the treatment reported.

The medical community is closely watching infigratinib because it is an oral medication, whereas the only currently FDA-approved treatment, BioMarin’s Voxzogo, requires a daily injection. Analysts suggest that even if the efficacy were only comparable to injectables, the convenience of an oral pill could lead up to half of all patients to switch treatments. BridgeBio’s therapy works by blocking the FGFR3 protein, which normally stalls bone growth by preventing cartilage cells from maturing.

Fueled by these results, BridgeBio plans to submit marketing applications to regulators in the second half of 2026. The company also intends to accelerate the development of the drug for hypochondroplasia, another genetically driven form of dwarfism. Following the announcement, BridgeBio’s stock price surged by more than 15%, reflecting investor confidence in the drug's potential to become the "treatment of choice" in a multi-billion dollar market.

---

🔖 Sources

BridgeBio rises after late-stage trial win for dwarfism therapy

BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis

---

Keywords: Infigratinib for Achondroplasia

Infigratinib for Achondroplasia

---